TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes
Brief Summary: The purpose of this study is to assess the long term safety and effectiveness of three doses of vildagliptin, an unapproved drug, compared to placebo in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.


Options:
A: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A
D: Arm Label: Sitagliptin 100 mg/100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin (MK0431), Drug: Metformin - Rescue | Arm Label: Sitagliptin 200 mg/200 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin, Drug: Metformin - Rescue | Arm Label: Placebo/Sitagliptin 100 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin - Rescue | Arm Label: Placebo/Sitagliptin 200 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin - Rescue | Intervention Type: DRUG; Name: Sitagliptin (MK0431); Assigned to Arm(s): Sitagliptin 100 mg/100 mg | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin 200 mg/200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Sitagliptin 200 mg | Intervention Type: DRUG; Name: Metformin - Rescue; Assigned to Arm(s): Placebo/Sitagliptin 100 mg, Placebo/Sitagliptin 200 mg, Sitagliptin 100 mg/100 mg, Sitagliptin 200 mg/200 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of Cellulose Sulfate Gel and HIV in Nigeria
Brief Summary: This is a Phase 3, multi-center, randomized, placebo-controlled trial to determine the effectiveness and safety of the 6% cellulose sulfate (CS) vaginal gel for the prevention of HIV infection.


Options:
A: Intervention Type: DRUG; Name: Carraguard (PC-515); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Cellulose Sulfate Vaginal Gel (Microbicide); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: 1.0% C31G SAVVY vaginal gel; Assigned to Arm(s): N/A
D: Arm Label: Dapivirine Vaginal Ring; Type: EXPERIMENTAL; Interventions: Combination Product: Dapivirine Vaginal Ring | Arm Label: Placebo Ring; Type: PLACEBO_COMPARATOR; Interventions: Combination Product: Placebo Ring | Intervention Type: COMBINATION_PRODUCT; Name: Dapivirine Vaginal Ring; Assigned to Arm(s): Dapivirine Vaginal Ring | Intervention Type: COMBINATION_PRODUCT; Name: Placebo Ring; Assigned to Arm(s): Placebo Ring

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of the Efficacy of Candidate HPV 16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Adolescent & Young Adult Women in North America and Brazil Vaccinated in Primary Study 580299/001
Brief Summary: Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get cervical cancer. This is an observer blind follow up study of the study HPV-001, which evaluated the ability of the HPV vaccine to prevent HPV infection. The current study invites all of the 1113 subjects in the HPV-001 study that received all three doses of vaccine/placebo to be enrolled and followed-up for several additional years to see if the HPV vaccine prevents HPV-16 and HPV-18 infections and to evaluate the safety of the vaccine. Subjects will remain in the same study group as in the primary study. No vaccine or placebo will be administered in this study.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: 3-dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: 2-dose; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: 2 doses by default; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: Single-dose; Type: EXPERIMENTAL; Interventions: Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Arm Label: Unvaccinated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®); Assigned to Arm(s): 2 doses by default, 2-dose, 3-dose, Single-dose
B: Arm Label: Patients; Type: OTHER; Interventions: Other: Human papilloma virus vaccine (cervarix) | Intervention Type: OTHER; Name: Human papilloma virus vaccine (cervarix); Assigned to Arm(s): Patients
C: Intervention Type: BIOLOGICAL; Name: HPV 16/18 VLP AS04; Assigned to Arm(s): N/A
D: Arm Label: Cervarix™ & Twinrix™ Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™, Biological: Twinrix ™ Paediatric | Arm Label: Cervarix™ Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Twinrix™ Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Twinrix ™ Paediatric | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix™ & Twinrix™ Group, Cervarix™ Group | Intervention Type: BIOLOGICAL; Name: Twinrix ™ Paediatric; Assigned to Arm(s): Cervarix™ & Twinrix™ Group, Twinrix™ Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lupus Atherosclerosis Prevention Study
Brief Summary: Cardiovascular disease, specifically from atherosclerosis, is the major cause of mortality in systemic lupus erythematosus (SLE) in developed countries. Coronary artery disease and stroke contribute to long-term morbidity in surviving patients. Atherosclerosis in SLE is multifactorial, with immune/inflammatory endothelial damage, traditional cardiovascular risk factors, and prothrombotic factors all playing important roles. Multiple groups have shown that hyperlipidemia is predictive of later atherosclerosis in SLE. In the general population, statins have become the drug of choice in preventing atherosclerotic events, through two mechanisms: lipid lowering that helps to prevent progression, and stabilization of plaques to prevent rupture. In the Lupus Atherosclerosis Prevention Trial we will determine if atorvastatin reduces the progression of atherosclerosis on helical computed tomography (CT) and carotid duplex. Recent work has confirmed that statins have an immunomodulatory role. This study will also determine whether statins improve clinical lupus activity or lupus serologies (anti-dsDNA and complement).


Options:
A: Arm Label: Group 1 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 2 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 3 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 4 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 5 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 6 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 7 without atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Arm Label: Group 8 with atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: REGN727(SAR236553) | Intervention Type: DRUG; Name: REGN727(SAR236553); Assigned to Arm(s): Group 1 with atorvastatin, Group 2 with atorvastatin, Group 3 with atorvastatin, Group 4 with atorvastatin, Group 5 with atorvastatin, Group 6 with atorvastatin, Group 7 without atorvastatin, Group 8 with atorvastatin
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AutoPulse Assisted Prehospital International Resuscitation Trial (ASPIRE)
Brief Summary: The AutoPulse Assisted Prehospital International Resuscitation (ASPIRE) Trial compares the efficacy of circulatory assist by manual chest compression versus an automated chest compression device (AutoPulse™) during the resuscitative attempt following out-of-hospital cardiac arrest.


Options:
A: Arm Label: 1:Mechanical CPR with LUCAS; Type: EXPERIMENTAL; Interventions: Device: LUCAS | Arm Label: 2 Manual CPR; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional manual resuscitation method | Intervention Type: DEVICE; Name: LUCAS; Assigned to Arm(s): 1:Mechanical CPR with LUCAS | Intervention Type: OTHER; Name: Conventional manual resuscitation method; Assigned to Arm(s): 2 Manual CPR
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: AutoPulse | Arm Label: 2; Type: OTHER; Interventions: Other: Manual | Intervention Type: DEVICE; Name: AutoPulse; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Manual; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Impedance Threshold Device (ITD) | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham ITD | Arm Label: 3; Type: OTHER; Interventions: Other: Analyze early | Arm Label: 4; Type: OTHER; Interventions: Other: Analyze later | Intervention Type: DEVICE; Name: Impedance Threshold Device (ITD); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Sham ITD; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Analyze early; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Analyze later; Assigned to Arm(s): 4
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: AutoPulse | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual CPR | Intervention Type: DEVICE; Name: AutoPulse; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Manual CPR; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Advair - CRP Study
Brief Summary: Large population-based studies suggest that patients with chronic obstructive pulmonary disease (COPD) are 2 to 3 times at risk for cardiovascular mortality, which accounts for a large proportion of the total number of deaths. How COPD increases the risk of poor cardiovascular outcomes is largely unknown. However, there is growing evidence that persistent low-grade systemic inflammation is present in COPD and that this may contribute to the pathogenesis of atherosclerosis and cardiovascular disease among COPD patients. Inflammation and more specifically, C-reactive protein (CRP), has been linked with all stages of atherosclerosis, including plaque genesis, rupture and subsequent thrombo-fibrosis of vulnerable vessels. Recently, our group has demonstrated in a relatively small study that short-term inhaled corticosteroid (ICS) therapy can repress serum CRP levels in stable COPD patients. Conversely, withdrawal of ICS leads to a marked increase in serum CRP levels. Although very promising, these data cannot be considered definitive because the study was small in size and scope (N=41 patients). Additionally, this study did not address the potential effects of combination therapy with ICS and long-acting β2 agonists (LABA). This is an important short-coming because combination therapy of ICS and LABA have been shown to produce improved clinical outcomes over ICS monotherapy and is commonly used by clinicians in the treatment of moderate to severe COPD. We hypothesize that inhaled fluticasone (Flovent®) reduces systemic inflammation and that combination therapy (Advair®) is more effective than steroids alone in reducing systemic inflammation in COPD. In this proposal, we will implement a randomized controlled trial to determine whether ICS by themselves or in combination with LABAs can:

1. reduce CRP levels in stable COPD patients and
2. reduce other pro-inflammatory cytokines, which have been linked with cardiovascular morbidity and mortality such as interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1)


Options:
A: Intervention Type: DRUG; Name: Advair; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Flovent; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: OTHER; Interventions: Drug: Fluticasone | Arm Label: 2; Type: OTHER; Interventions: Drug: Fluticasone, Drug: Comparator: Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Budesonide pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study of MEDI-524 (Motavizumab), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prevention of RSV Disease Among Native American Infants in the Southwestern United States
Brief Summary: MI-CP117 was a Phase 3, randomized, double-blind, placebo-controlled trial designed to determine if motavizumab is more effective than placebo in reducing RSV hospitalization in otherwise healthy Native American Infants in the Southwestern United States during their first RSV season.


Options:
A: Intervention Type: DRUG; Name: Amoxycillin; Assigned to Arm(s): N/A
B: Arm Label: Treated; Type: N/A; Interventions: N/A | Arm Label: Untreated; Type: N/A; Interventions: N/A
C: Arm Label: Experimental; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxicillin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): Control
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Motavizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Motavizumab | Intervention Type: BIOLOGICAL; Name: Motavizumab; Assigned to Arm(s): Motavizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Chlorhexidine Vaginal and Infant Wash to Reduce Neonatal Mortality
Brief Summary: Infection is a major health problem during birth in Pakistan. This study will look at the possibility of using a septic wash to help improve health during birth in Karachi, Pakistan.


Options:
A: Arm Label: Chlorhexidine; Type: EXPERIMENTAL; Interventions: Procedure: Chlorhexidine vaginal and infant wash | Intervention Type: PROCEDURE; Name: Chlorhexidine vaginal and infant wash; Assigned to Arm(s): Chlorhexidine
B: Intervention Type: BEHAVIORAL; Name: Newborn skin cleansing with 0.25% chlorhexidine solution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cleansing of umbilical cord with soap and water solution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cleansing of umbilical cord with 4% chlorhexidine; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Newborn Thermal Care Practice; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: 4% Chlorhexidine | Arm Label: B; Type: EXPERIMENTAL; Interventions: Other: Hand washing Soap | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: 4% Chlorhexidine | Arm Label: D; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 4% Chlorhexidine; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Hand washing Soap; Assigned to Arm(s): B | Intervention Type: DRUG; Name: 4% Chlorhexidine; Assigned to Arm(s): C

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Chlorhexidine Vaginal and Infant Wash to Reduce Neonatal Mortality
Brief Summary: Infection is a major health problem during birth in Pakistan. This study will look at the possibility of using a septic wash to help improve health during birth in Karachi, Pakistan.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: 4% Chlorhexidine | Arm Label: B; Type: EXPERIMENTAL; Interventions: Other: Hand washing Soap | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: 4% Chlorhexidine | Arm Label: D; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 4% Chlorhexidine; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Hand washing Soap; Assigned to Arm(s): B | Intervention Type: DRUG; Name: 4% Chlorhexidine; Assigned to Arm(s): C
B: Arm Label: Chlorhexidine; Type: EXPERIMENTAL; Interventions: Procedure: Chlorhexidine vaginal and infant wash | Intervention Type: PROCEDURE; Name: Chlorhexidine vaginal and infant wash; Assigned to Arm(s): Chlorhexidine
C: Intervention Type: BEHAVIORAL; Name: Newborn skin cleansing with 0.25% chlorhexidine solution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cleansing of umbilical cord with soap and water solution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cleansing of umbilical cord with 4% chlorhexidine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Chlorhexidine, Procedure: Birth canal wipe | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: sterile water external genital wipe | Intervention Type: DRUG; Name: Chlorhexidine; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Birth canal wipe; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: sterile water external genital wipe; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Latex Diaphragm to Prevent HIV Acquisition Among Women: A Female-Controlled, Physical Barrier of the Cervix
Brief Summary: The purpose of this trial is to determine whether using the diaphragm and a lubricant get can reduce women's risk of acquiring an HIV infection.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Eban HIV/STD Risk Reduction Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Eban Health Promotion Intervention | Intervention Type: BEHAVIORAL; Name: Eban HIV/STD Risk Reduction Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Eban Health Promotion Intervention; Assigned to Arm(s): 2
B: Arm Label: Group A; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Lecture-format presentation | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interactive Injection Risk Intervention | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interactive Sexual Risk Intervention | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive injection and sexual risk intervention | Intervention Type: BEHAVIORAL; Name: Interactive injection and sexual risk intervention; Assigned to Arm(s): Group D | Intervention Type: BEHAVIORAL; Name: Interactive Sexual Risk Intervention; Assigned to Arm(s): Group C | Intervention Type: BEHAVIORAL; Name: Interactive Injection Risk Intervention; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: Lecture-format presentation; Assigned to Arm(s): Group A
C: Intervention Type: DEVICE; Name: Ortho All-Flex diaphragm and Replens lubricant gel; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: HORIZONS HIV Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: enhanced standard-of-care | Intervention Type: BEHAVIORAL; Name: HORIZONS HIV Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: enhanced standard-of-care; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Latex Diaphragm to Prevent HIV Acquisition Among Women: A Female-Controlled, Physical Barrier of the Cervix
Brief Summary: The purpose of this trial is to determine whether using the diaphragm and a lubricant get can reduce women's risk of acquiring an HIV infection.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Families Talking Together | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control on hygiene and nutrition | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Active control on hygiene and nutrition; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Families Talking Together; Assigned to Arm(s): 1
B: Intervention Type: DEVICE; Name: Ortho All-Flex diaphragm and Replens lubricant gel; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health Improvement Project for Teens on HIV Prevention | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Health Improvement Project for Teens on HIV Prevention | Intervention Type: BEHAVIORAL; Name: Health Improvement Project for Teens on HIV Prevention; Assigned to Arm(s): 1, 2
D: Intervention Type: BEHAVIORAL; Name: Increased access to emergency contraceptive pills; Assigned to Arm(s): N/A

Answer: B